Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients
Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by muscle weakness and caused by pathogenic autoantibodies that bind to membrane proteins at the neuromuscular junction. Most patients have autoantibodies against the acetylcholine receptor (AChR), but a subset of patients have au...
Autors principals: | Takata, K, Stathopoulos, P, Cao, M, Mané-Damas, M, Fichtner, M, Benotti, E, Jacobson, L, Waters, P, Irani, S, Martinez-Martinez, P, Beeson, D, Losen, M, Vincent, A, Nowak, R, O'Connor, K |
---|---|
Format: | Journal article |
Publicat: |
American Society for Clinical Investigation
2019
|
Ítems similars
-
Diagnostic use of autoantibodies in myasthenia gravis.
per: Leite, M, et al.
Publicat: (2010) -
Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy
per: Miriam L. Fichtner, et al.
Publicat: (2022-10-01) -
Silencing of Dok-7 in adult rat muscle increases susceptibility to passive transfer myasthenia gravis
per: Gomez, A, et al.
Publicat: (2016) -
Myasthenia gravis complement activity is independent of autoantibody titer and disease severity.
per: Miriam L Fichtner, et al.
Publicat: (2022-01-01) -
Myasthenia gravis complement activity is independent of autoantibody titer and disease severity
per: Miriam L. Fichtner, et al.
Publicat: (2022-01-01)